ASPPH logo

Connect

Partner News

Partner News

DHHS Funding Opportunities

FUNDING OPPORTUNITIES from the Department of Health and Human Services (DHHS)

________________________________________________________________________

Department of Health and Human Services – Administration for Community Living – Alzheimer’s Disease Programs Initiative-Grants to States and Communities (Round Two)

Proposal Due Date:                                                           August 20, 2021                

Expected Number of Awards:                                       13

Estimated Total Program Funding:                            $11,037,723

Award Ceiling:                                                                    $1,000,000

Award Floor:                                                                       $550,000

Funding Opportunity Number:                                    HHS-2021-ACL-AOA-ADPI-0086

Purpose: Alzheimer’s Disease Program Initiative (ADPI) cooperative agreements are dedicated to the development and expansion of dementia-capable home and community-based service (HCBS) systems in States and Communities. There will be two application options through this opportunity, one for States (Option A) and the other for Communities (Option B).  No entity would be eligible to apply for both State and Community options. The systems resulting from program activities under both program options will provide quality, person-centered services that help individuals remain independent and safe in their communities. 

https://www.grants.gov/web/grants/view-opportunity.html?oppId=331701

Department of Health and Human Services – Centers for Medicare & Medicaid Services – Cooperative Agreement to Support Navigators in Federally-facilitated Exchanges

Proposal Due Date:                                                           July 6, 2021

Expected Number of Awards:                                        120    

Estimated Total Program Funding:                            $80,000,000

Award Ceiling:                                                                    $0      

Award Floor:                                                                       $0      

Funding Opportunity Number:                                   CA-NAV-21-001

Purpose: The Cooperative Agreement to Support Navigators in Federally-facilitated Exchanges (Funding Opportunity) will enable recipients to operate as Exchange Navigators in States with a Federally-facilitated Marketplace (FFM) for benefit years 2022 through 2024.

Entities or individuals eligible to apply for funding through this Funding Opportunity must be capable of carrying out, at a minimum, all Navigator duties required by the ACA and HHS regulations. The primary regulations that establish requirements for awardees under this Funding Opportunity are 45 C.F.R. §§ 155.210 and 155.215. These regulations establish duties that are required of all recipients of funding under this Funding Opportunity, including, but not limited to:

https://www.grants.gov/web/grants/view-opportunity.html?oppId=332990

Department of Health and Human Services – Health Resources and Services Administration – Delta Region Rural Health Workforce Training Program

Proposal Due Date:                                                           July 9, 2021

Expected Number of Awards:                                       4         

Estimated Total Program Funding:                           $2,000,000 

Award Ceiling:                                                                   $0      

Award Floor:                                                                      $0      

Funding Opportunity Number:                                   HRSA-21-105

Purpose: This notice announces the opportunity to apply for funding under the Delta Region Rural Health Workforce Training Program. The purpose of this program is to educate and train future and current health professionals in the rural counties and parishes of the Mississippi River Delta Region and Alabama Black Belt (Delta Regional Authority (DRA) region) in the following critical administrative support occupations: medical coding and billing, claims processing, information management, and clinical documentation. This program supports HRSA’s collaboration with the Delta Regional Authority (DRA) to enhance healthcare delivery in the rural counties and parishes of the DRA region, and addresses a key area of need identified by DRA and rural healthcare organizations in the region. The Delta Region Rural Health Workforce Training Program addresses the ongoing need in healthcare facilities for trained administrative support or business operations professionals in rural communities through the development of Strategic Networks that support recruitment, formal training, certification, and placement of students. This program aims to provide training and pathways to professional certifications to current administrative support professionals working in rural DRA region healthcare facilities as well as new entrants to the workforce1 and dislocated workers.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333184

Department of Health and Human Services – National Institutes of Health – Non-Human Primate Developmental Genotype-Tissue Expression (NHP dGTEx) Project (U24 Clinical Trials Not Allowed)

Letter of Intent Due Date:                                              30 days prior to application due date

Proposal Due Date:                                                           August 2, 2021                  

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                                      RFA-HG-21-026

Purpose: The purpose of this funding opportunity is to solicit applications for the Non-Human Developmental Genotype-Tissue Expression (NHP dGTEx) Research Center. The NHP dGTEx research center will perform four major functions: 1) create a tissue resource of multiple reference tissues across developmental stages in non-human primates (NHPs); 2) perform transcriptome sequencing and other genomic analysis of bulk tissues and single-cell populations; 3) perform analysis of gene expression patterns in NHPs and compare them to human gene expression patterns; and 4) make the tissue samples and data available and usable to the community.)

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333995

Department of Health and Human Services – National Institutes of Health – Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Diagnostic-Telemedicine Resource (U24 Clinical Trial Not Allowed)

Letter of Intent Due Date:                                              July 15, 2021

Proposal Due Date:                                                           August 16, 2021                

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                                    RFA-AA-21-012

Purpose: The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (U24) applications in response to this FOA should propose the Diagnostic-Telemedicine Core (U24) component of the CIFASD consortium.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333941

Department of Health and Human Services – National Institutes of Health – Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Administrative Resource (U24 Clinical Trial Not Allowed)

Letter of Intent Due Date:                                              July 15, 2021

Proposal Due Date:                                                           August 16, 2021                

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                                    RFA-AA-21-011

Purpose:  The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (U24) applications in response to this FOA should propose the Administrative Resource (U24) component of the CIFASD consortium.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333965

Department of Health and Human Services – National Institutes of Health – Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Data Coordination Resource (U24 Clinical Trial Not Allowed)

Letter of Intent Due Date:                                              July 15, 2021

Proposal Due Date:                                                           August 16, 2021                

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                                     RFA-AA-21-013

Purpose:  The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD.  Cooperative Agreement (U24) applications in response to this FOA should propose the Data Coordination Core (U24) component of the CIFASD consortium.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333942

Department of Health and Human Services – National Institutes of Health – Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Developmental Project (UH2 Clinical Trial Optional)

Letter of Intent Due Date:                                              July 15, 2021

Proposal Due Date:                                                           August 16, 2021                

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                                     RFA-AA-21-014

Purpose:  The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD.  Cooperative Agreement (UH2) applications in response to this FOA should propose exploratory/developmental projects of the CIFASD consortium.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333943

Department of Health and Human Services – National Institutes of Health – Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Project (U01 Clinical Trial optional)

Letter of Intent Due Date:                                              July 15, 2021

Proposal Due Date:                                                           August 16, 2021                

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                                     RFA-AA-21-010

Purpose: The National Institute on Alcohol Abuse and Alcoholism (NIAAA) seeks applications to continue the previously funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD). Responsive applications are expected to address urgent and important unmet needs in the fetal alcohol spectrum disorders (FASD) field through an integrated and multidisciplinary research approach. These unmet needs include identifying FASD cases early and accurately, improving interventions to mitigate FASD outcomes; expanding basic and mechanistic understanding of alcohol teratogenesis aimed at accelerated translation, and reducing prenatal alcohol exposure and the incidence of FASD. Cooperative Agreement (U01) applications in response to this FOA should propose individual clinical or basic research projects.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333964

Department of Health and Human Services National Institutes of Health – NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)

Proposal Due Date:                                                           September 1, 2021

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                                    RFA-RM-21-017

Purpose: The NIH Directors Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the research workforce. Individuals from diverse backgrounds and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. In addition, applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in a broad area of relevance to the NIH. The NIH Directors Transformative Research Award is a component of the High-Risk, High-Reward Research program of the NIH Common Fund.
http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-21-017.html

Department of Health and Human Services National Institutes of Health – The Early Detection Research Network: Clinical Validation Centers (U01 Clinical Trial Optional)

Letter of Intent Due Date:                                    30 days prior to the application due date

Proposal Due Date:                                                  September 9, 2021

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                           RFA-CA-21-033

Purpose: The purpose of this FOA is to solicit applications for Clinical Validation Centers (CVCs); one of the three scientific units of the Early Detection Research Network (EDRN). EDRN (http://edrn.nci.nih.gov/) is an integrated infrastructure to develop and validate biomarkers and imaging methods for the detection of early stage cancers and risk assessment. Clinical Validation Centers (CVCs) will conduct research to validate biomarkers and/or imaging methods for risk assessment and detection of early stage cancers. CVCs will also serve as resource centers for collaborative research within the EDRN by providing high-quality specimens for phase 1 and 2 biomarker refinement studies to other EDRN scientific units, as well as for conducting Network collaborative biomarker validation studies. The CVCs must also have the expertise and ability to conduct Phase 4 clinical utility trials of validated early detection biomarkers and/or imaging methods.

The other two scientific units of the EDRN are the Biomarker Characterization Centers (BCCs), which will (1) discover, develop, characterize and test new biomarkers or refine existing biomarkers, (2) develop, refine and/or standardize biomarker assays, (3) provide resources and support for the validation of biomarkers developed by the EDRN, and (4) participate in collaborative projects with other laboratories and centers; and the Data Management and Coordinating Center (DMCC), which will support statistical and computational analyses, informatics infrastructure, study design, coordination and management of EDRN-sponsored biomarker validation studies, and the coordination of Network-wide meetings and workshops.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333931

Department of Health and Human Services National Institutes of Health – The Early Detection Research Network: Data Management and Coordinating Center (U24 Clinical Trial Not Allowed)

Letter of Intent Due Date:                                              30 days prior to the application due date

Proposal Due Date:                                                           September 9, 2021

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                                      RFA-CA-21-034

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for a Data Management and Coordinating Center (DMCC), one of the three scientific units of the Early Detection Research Network (EDRN). The EDRN is a national infrastructure to discover, develop, and validate biomarkers and imaging methods for early cancer detection and risk assessment. The proposed DMCC will be responsible for the following activities: 1) Network Coordination, 2) Data Science, Data Management and Study Protocol Development, 3) Validation Study Infrastructure and Services, and 4) EDRN Core Fund Management.

The other two scientific units of the continuing EDRN program are the Biomarker Characterization Centers (BCCs), which will be responsible for both biomarker development and assay development and standardization; and the Clinical Validation Centers (CVCs), which will conduct clinical research on the validation of biomarkers and imaging methods and will serve as resource centers for the Network by participating in collaborative biomarker validation studies with EDRN BCCs.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333949

Department of Health and Human Services National Institutes of Health – The Early Detection Research Network: Biomarker Characterization Centers (U2C Clinical Trial Not Allowed)

Letter of Intent Due Date:                                              30 days prior to the application due date

Proposal Due Date:                                                           September 9, 2021

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                                      RFA-CA-21-035

Purpose: The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for Biomarker Characterization Centers (BCCs), one of the three scientific units of the Early Detection Research Network (EDRN). The EDRN is a national infrastructure to discover, develop, and validate biomarkers and imaging methods for early cancer detection and risk assessment. BCCs will (1) discover, develop, characterize and test new biomarkers or refine existing biomarkers, (2) develop, refine and/or standardize biomarker assays, (3) provide resources and support for the validation of biomarkers developed by the EDRN, and (4) participate in collaborative projects with other laboratories and centers. The other two scientific units of the continuing EDRN program are the Clinical Validation Centers (CVCs), which will conduct clinical research on the validation of biomarkers and will serve as resource centers for the Network by participating in collaborative biomarker validation studies with EDRN BCCs; and the Data Management and Coordinating Center (DMCC), which will support statistical and computational analyses, informatics infrastructure, study design, coordination and management of EDRN-sponsored biomarker validation studies, and the coordination of Network-wide meetings and workshops.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333948

Department of Health and Human Services National Institutes of Health – Shared Personal Protective Equipment (PPE) Resources (S10 Clinical Trial Not Allowed)

date Proposal Due Date:                                                 September 24, 2021

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                                    PAR-21-257

Purpose: The National Institutes of Health (NIH) hereby notifies the applicant community that funds may be available to provide Personal Protective Equipment (PPE) to directly support the needs of clinical trials and clinical research (CT/CR) activities supported by NIH grants and cooperative agreements. This program will ensure that adequate protective equipment is available and distributed across clinical sites to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in clinical trials and clinical studies.

Only applications submitted in response to a Notice of Special Interest (NOSI) published by an IC will be allowed to apply to this FOA. The NOSI will outline which NIH funded CT/CR programs are eligible to apply.

Types of PPE supported by this FOA include but are not limited to:

Masks

Gloves

Gowns and coveralls

Safety glasses

Face shields

Head caps

Shoe covers

Shield wipes

https://www.grants.gov/web/grants/view-opportunity.html?oppId=334027

Department of Health and Human Services National Institutes of Health – Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33 Clinical Trials Not Allowed)

Letter of Intent Due Date:                                  September 14, 2021

Proposal Due Date:                                               October 14, 2021

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                         RFA-DA-22-016

Purpose: The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship between sleep and substance use disorders (SUDs). These mechanistic studies will not only offer an insight into the fundamental processes that link substance use disorders to disorders of sleep regulation and vice-versa but may also have implications for managing risk for the development of SUDs and identifying new targets for prevention and therapeutics.

https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-016.html

Department of Health and Human Services National Institutes of Health – Characterization of Islet-derived Extracellular Vesicles for Improved Detection, Monitoring, Classification, and Treatment of Type 1 Diabetes (R01 Clinical Trial Not Allowed)

Letter of Intent Due Date:                                  October 3, 2021

Proposal Due Date:                                               November 3, 2021

Expected Number of Awards:                                       

Estimated Total Program Funding:                             

Award Ceiling:                                                                   

Award Floor:                                                                      

Funding Opportunity Number:                         RFA-DK-21-016

Purpose: This initiative will support the development of tools and experimental platforms for the purification and characterization of Extracellular Vesicles (EV) originating from the human pancreatic islet and its broader tissue environment in healthy individuals, and individuals with T1D or at-risk of developing the disease. It will also support the exploration of the contribution of pancreatic EV biology to islet function, dysfunction and T1D disease initiation; the development of EV-based diagnostic tools for disease monitoring and classification; and the use of pancreatic EV biology to identify novel therapeutic targets.

https://www.grants.gov/web/grants/view-opportunity.html?oppId=333977